Shlomo Yanai - Perrigo Company Independent Director Nominee
PRGO Stock | USD 31.23 0.74 2.43% |
Director
Mr. Shlomo Yanai is Independent Director Nominee of the Company. He served as Chief Executive Officer and as President of Teva Pharmaceutical Industries Ltd., a global pharmaceutical company, from March 2007 to May 2012. He was an independent director of Sagent Pharmaceuticals, Inc., since April 2015 a director of Quinpario Acquisition Corporationration 2 since November 2014 a director and NonExecutive Chairman of Cambrex since November 2012 and a director of Lumenis Ltd. since December 2012. He also serves as a member of an advisory board at Paragon Pharmaceuticals, LLC a member of the International Advisory Board of the MBA program of BenGurion University as well as an honorary member of the board of the Universitys Institute for Policy and Strategy of the Interdisciplinary Center. Mr. Yanai also served 32 years with the Israeli Defense forces, retiring in 2001 with the rank of Major General.
Age | 62 |
Address | The Sharp Building, Dublin, Ireland, D02 TY74 |
Phone | 353 1 709 4000 |
Web | https://www.perrigo.com |
Shlomo Yanai Latest Insider Activity
Tracking and analyzing the buying and selling activities of Shlomo Yanai against Perrigo Company stock is an integral part of due diligence when investing in Perrigo Company. Shlomo Yanai insider activity provides valuable insight into whether Perrigo Company is net buyers or sellers over its current business cycle. Note, Perrigo Company insiders must abide by specific rules, including filing SEC forms every time they buy or sell Perrigo Company'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Shlomo Yanai over six months ago Acquisition by Shlomo Yanai of 1759 shares of Philip Morris subject to Rule 16b-3 | ||
Shlomo Yanai over six months ago Exercise or conversion by Shlomo Yanai of 80128 shares of Amneal Pharmaceuticals subject to Rule 16b-3 |
Perrigo Company Management Efficiency
The company has return on total asset (ROA) of 0.0164 % which means that it generated a profit of $0.0164 on every $100 spent on assets. This is way below average. Perrigo Company's management efficiency ratios could be used to measure how well Perrigo Company manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of April 2024, Return On Tangible Assets is likely to grow to -0.0028. In addition to that, Return On Capital Employed is likely to drop to 0.02. At this time, Perrigo Company's Other Assets are very stable compared to the past year. As of the 25th of April 2024, Intangibles To Total Assets is likely to grow to 0.63, while Total Assets are likely to drop about 5.7 B.Similar Executives
Showing other executives | DIRECTOR Age | ||
Anupam Puri | Dr Reddys Laboratories | 69 | |
Charles Hinkaty | Prestige Brand Holdings | 64 | |
Mary Malanoski | Phibro Animal Health | 61 | |
Garen Bohlin | Collegium Pharmaceutical | 70 | |
Reuven Behar | Kamada | 60 | |
Natale Ricciardi | Prestige Brand Holdings | 71 | |
Ziv Kop | Kamada | 43 | |
Aarti Shah | Elanco Animal Health | 55 | |
Carol Wrenn | Phibro Animal Health | 57 | |
Mark Froimson | Pacira Pharmaceuticals | 57 | |
Art Garcia | Elanco Animal Health | 59 | |
James Jenness | Prestige Brand Holdings | 73 | |
Prasad Menon | Dr Reddys Laboratories | 74 | |
Asaf Frumerman | Kamada | N/A | |
Michael Ross | Deciphera Pharmaceuticals LLC | 68 | |
Steven Ratoff | Eagle Pharmaceuticals | 81 | |
David Ricks | Elanco Animal Health | 52 | |
David Pernock | Eagle Pharmaceuticals | 63 | |
Jonathan Hahn | Kamada | 32 | |
Kalpana Morparia | Dr Reddys Laboratories | 71 | |
Sam Gejdenson | Phibro Animal Health | 70 |
Management Performance
Return On Equity | -9.0E-4 | ||||
Return On Asset | 0.0164 |
Perrigo Company Leadership Team
Elected by the shareholders, the Perrigo Company's board of directors comprises two types of representatives: Perrigo Company inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Perrigo. The board's role is to monitor Perrigo Company's management team and ensure that shareholders' interests are well served. Perrigo Company's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Perrigo Company's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Hendrickson, President | ||
Gary Cohen, Independent Director | ||
Arthur Shannon, IR Contact Officer | ||
Svend Andersen, Executive Vice President and President - Consumer Healthcare International | ||
Judy Brown, CFO and Executive VP | ||
Laurie Brlas, Independent Director | ||
Donal OConnor, Independent Director | ||
James Michaud, Chief Human Resource Officer, Executive Vice President | ||
Theodore Samuelsto, Independent Director | ||
Scott Jamison, Executive Vice President General Manager - Nutritionals | ||
Ellen Hoffing, Independent Director | ||
Marc Coucke, Executive Vice President General Manager - Omega Pharma Business | ||
Thomas Farrington, Executive Vice President, Chief Information Officer | ||
Jeffrey Needham, Executive Vice President General Manager - Consumer Healthcare | ||
Todd Kingma, Executive Vice President, General Counsel, Company Secretary | ||
Rolf Classon, Independent Chairman of the Board | ||
Patrick LockwoodTaylor, CEO President | ||
Raymond Silcock, Chief Financial Officer, Executive Vice President | ||
Shlomo Yanai, Independent Director Nominee | ||
Michael Stewart, Senior Vice President - Global Human Resources | ||
Jeffrey Kindler, Independent Director | ||
Jacqualyn Fouse, Independent Director | ||
Grainne Quinn, Executive Vice President Chief Medical Officer | ||
Mary ReillyBrest, Director Development | ||
Murray Kessler, President, Chief Executive Officer, Director | ||
Erica Mann, Independent Director | ||
Kyle Hanson, General VP | ||
Richard Sorota, Executive Vice President, General Manager - of Consumer Self-Care Americas | ||
Gary Kunkle, Lead Independent Director | ||
Katherine Doyle, Independent Director | ||
Joseph Papa, Chairman and CEO | ||
Catherine Schmelter, Executive Optimization | ||
Bradley Alford, Independent Director | ||
Alison Ives, Executive Officer | ||
Jeffrey Smith, Independent Director | ||
James Dillard, Executive Vice President, President - Consumer Self-Care Americas | ||
Douglas Boothe, Executive Vice President General Manager - Rx Pharmaceuticals | ||
Orlando Ashford, Independent Director | ||
Ronald Winowiecki, Acting CFO | ||
Louis Yu, Executive Vice President - Global Quality | ||
John Wesolowski, Executive Vice President and Presidentident - RX | ||
Adriana Karaboutis, Independent Director | ||
Michael Jandernoa, Independent Director | ||
Shannon Hukill, Director Operations | ||
Paul Weninger, Executive Vice President - Global Quality Operations | ||
Herman Morris, Independent Director | ||
Jatin Shah, Senior Vice President Chief Scientific Officer | ||
Robert Willis, Chief Human Resource Officer, Executive Vice President | ||
Theodore Samuels, Independent Director | ||
Eduardo Bezerra, Executive CFO | ||
Geoffrey Parker, Independent Director | ||
Sharon Kochan, Executive Vice President, President - RX Pharmaceuticals | ||
Marry Brlas, Independent Chairman of the Board | ||
James III, Ex Americas | ||
Bradley Joseph, Vice Communications | ||
Ronald Janish, Executive Vice President - Global Operations and Supply Chain, Chief Transformation Officer | ||
Uwe Rohrhoff, President CEO, Director |
Perrigo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Perrigo Company a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -9.0E-4 | ||||
Return On Asset | 0.0164 | ||||
Profit Margin | (0) % | ||||
Operating Margin | 0.08 % | ||||
Current Valuation | 7.66 B | ||||
Shares Outstanding | 135.52 M | ||||
Shares Owned By Insiders | 0.30 % | ||||
Shares Owned By Institutions | 99.47 % | ||||
Number Of Shares Shorted | 3.86 M | ||||
Price To Earning | 23.57 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Perrigo Company using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Perrigo Company PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Perrigo Company information on this page should be used as a complementary analysis to other Perrigo Company's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Perrigo Stock analysis
When running Perrigo Company's price analysis, check to measure Perrigo Company's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perrigo Company is operating at the current time. Most of Perrigo Company's value examination focuses on studying past and present price action to predict the probability of Perrigo Company's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perrigo Company's price. Additionally, you may evaluate how the addition of Perrigo Company to your portfolios can decrease your overall portfolio volatility.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is Perrigo Company's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Perrigo Company. If investors know Perrigo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Perrigo Company listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.64) | Dividend Share 1.092 | Earnings Share (0.03) | Revenue Per Share 34.409 | Quarterly Revenue Growth 0.001 |
The market value of Perrigo Company is measured differently than its book value, which is the value of Perrigo that is recorded on the company's balance sheet. Investors also form their own opinion of Perrigo Company's value that differs from its market value or its book value, called intrinsic value, which is Perrigo Company's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Perrigo Company's market value can be influenced by many factors that don't directly affect Perrigo Company's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Perrigo Company's value and its price as these two are different measures arrived at by different means. Investors typically determine if Perrigo Company is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Perrigo Company's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.